Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test.

Veracyte has completed enrollment for the NIGHTINGALE trial, a clinical utility trial for its Percepta Nasal Swab lung cancer test. The trial aims to evaluate the test's impact on patient care for potentially cancerous lung nodules. The prospective, randomized, blinded study enrolled 2,400 patients across 90 US centers and will follow them for up to two years to assess the test's effectiveness in reducing unnecessary procedures and accelerating cancer treatment. The trial marks a significant step towards making the test widely available and guiding next steps for patients with lung nodules.